Ann: ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH, page-5

https://www.fiercebiotech.com/special-report/nash-four-letters-and-a-multibillion-dollar-opportunity

I like how the Heavy weights in the below linked article keep popping up ......Like Gilead or AstraZemeca etc....etc.. Especially now that the ' Front Runner ' selonsertib has been somewhat bumped out of contention.

Leaves a lot of room in a ' Multi Billion ' dollar market for other up and coming small Bio's with tremendous I.P and similar potential FAK ' inhibitor ' candidates....... Like Amplia Therapeutics......

Attached article above is a very good read about it.

" Gilead’s ASK1 inhibitor selonsertib had been among the NASH front-runners until this spring, when it failed to improve fibrosis in two phase 3 trials involving more than 1,600 patients. Though selonsertib may be dead in the water as a monotherapy, the company is testing it in combination with its FXR drug cilofexor and its ACC inhibitor firsocostat in a phase 2 study that should yield data by the end of the year. And that’s not all: Gilead is also testing the firsocostat-cilofexor combo with Novo Nordisk’s GLP-1 drug semaglutide. "

" AstraZeneca has cotadutide, a dual agonist of GLP-1 and glucagon, and Novartis has licogliflozin, an SGLT1/2 inhibitor. Both posted encouraging data at AASLD, improving enzyme levels and suggesting they might be advanced as treatments for NASH. Finally, Cirius Therapeutics is working on a second-generation thiazolidinedione, or TZD, a class of drugs used to treat diabetes. "